YU67202A - Farmaceutski preparati inhibitora glikogen fosforilaze - Google Patents

Farmaceutski preparati inhibitora glikogen fosforilaze

Info

Publication number
YU67202A
YU67202A YU67202A YUP67202A YU67202A YU 67202 A YU67202 A YU 67202A YU 67202 A YU67202 A YU 67202A YU P67202 A YUP67202 A YU P67202A YU 67202 A YU67202 A YU 67202A
Authority
YU
Yugoslavia
Prior art keywords
glycogen phosphorylase
pharmaceutical compositions
phosphorylase inhibitors
phosphorylase inhibitor
concentration
Prior art date
Application number
YU67202A
Other languages
English (en)
Inventor
Dennis Jay Hoover
Ravi Mysore Shanker
Dwayne Thomas Friesen
Douglas Alan Lorenz
James A. Schriver Nightingale
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU67202A publication Critical patent/YU67202A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Farmaceutski preparati sadrže inhibitor glikogen fosforilaze i najmanje jedan polimer za povećanje koncentracije. Preparat može biti prosta fizička smeša inhibitora glikogen fosforilaze i polimera za povećanje koncentracije ili disperzija inhibitora glikogen fosforilaze i polimera.[Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.
YU67202A 2000-03-16 2001-03-16 Farmaceutski preparati inhibitora glikogen fosforilaze YU67202A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
YU67202A true YU67202A (sh) 2006-01-16

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
YU67202A YU67202A (sh) 2000-03-16 2001-03-16 Farmaceutski preparati inhibitora glikogen fosforilaze

Country Status (32)

Country Link
US (1) US20010053778A1 (sh)
EP (1) EP1263414A1 (sh)
JP (1) JP2003526654A (sh)
KR (1) KR20020081445A (sh)
CN (1) CN1418089A (sh)
AP (1) AP2002002621A0 (sh)
AR (1) AR027656A1 (sh)
AU (1) AU2001242669A1 (sh)
BG (1) BG107037A (sh)
BR (1) BR0109189A (sh)
CA (1) CA2403241A1 (sh)
CO (1) CO5280087A1 (sh)
CZ (1) CZ20022955A3 (sh)
EA (1) EA200200858A1 (sh)
EE (1) EE200200530A (sh)
HU (1) HUP0204583A2 (sh)
IL (1) IL151320A0 (sh)
IS (1) IS6508A (sh)
MA (1) MA26882A1 (sh)
MX (1) MXPA02009097A (sh)
NO (1) NO20024386L (sh)
OA (1) OA12232A (sh)
PA (1) PA8513601A1 (sh)
PE (1) PE20011184A1 (sh)
PL (1) PL360780A1 (sh)
SK (1) SK12622002A3 (sh)
SV (1) SV2002000343A (sh)
TN (1) TNSN01040A1 (sh)
TR (1) TR200202184T2 (sh)
WO (1) WO2001068055A1 (sh)
YU (1) YU67202A (sh)
ZA (1) ZA200207290B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8562002A3 (en) * 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EA006777B1 (ru) 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
BR0210518A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
RS67304A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8974823B2 (en) * 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
PT3725778T (pt) 2012-09-11 2021-09-22 Astellas Pharma Inc Formulações de enzalutamida
CA3128535A1 (en) 2013-07-19 2015-01-22 Siga Technologies, Inc. Amorphous tecovirimat preparation
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832065T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer
SK72096A3 (en) * 1995-06-06 1997-11-05 Pfizer Indole-2-carboxamides, glycogen phosphorylase inhibitors and pharmauceutical compositions
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
MXPA02009097A (es) 2003-03-12
IS6508A (is) 2002-08-16
CN1418089A (zh) 2003-05-14
AU2001242669A1 (en) 2001-09-24
EA200200858A1 (ru) 2003-02-27
TR200202184T2 (tr) 2003-01-21
ZA200207290B (en) 2003-09-11
CA2403241A1 (en) 2001-09-20
SV2002000343A (es) 2002-07-03
PA8513601A1 (es) 2004-08-31
TNSN01040A1 (fr) 2005-11-10
EE200200530A (et) 2004-04-15
BG107037A (bg) 2003-04-30
OA12232A (en) 2006-05-10
PE20011184A1 (es) 2001-11-15
BR0109189A (pt) 2003-05-27
PL360780A1 (en) 2004-09-20
NO20024386D0 (no) 2002-09-13
HUP0204583A2 (hu) 2003-04-28
NO20024386L (no) 2002-11-13
EP1263414A1 (en) 2002-12-11
AR027656A1 (es) 2003-04-09
KR20020081445A (ko) 2002-10-26
JP2003526654A (ja) 2003-09-09
US20010053778A1 (en) 2001-12-20
CO5280087A1 (es) 2003-05-30
SK12622002A3 (sk) 2004-02-03
AP2002002621A0 (en) 2002-09-30
CZ20022955A3 (cs) 2003-09-17
WO2001068055A1 (en) 2001-09-20
IL151320A0 (en) 2003-04-10
MA26882A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
AP2002002621A0 (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
WO2006014647A3 (en) Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
AU2001294814A1 (en) Pumpcn compositions and uses thereof
SG150533A1 (en) 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
AP2001002235A0 (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
AU2003244110A1 (en) Flame retarder composition and flame retardant resin composition containing the composition
AU2001240978A1 (en) Glycogen phosphorylase inhibitor
WO2004014926A3 (fr) Alcoxyamines issues de nitroxydes βετα-phosphores, leur utilisation en polymerisation radicalaire
HK1042720A1 (en) Copolymer (composition) for modifying asphalt and asphalt compositions.
AU2001266926A1 (en) Hemostatic compositions, devices and methods
NO20011017D0 (no) Polymeriserings-inhibitering av styren-monomerer
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
AU2002228788A1 (en) Polymer containing granules and compositions thereof
AU4784900A (en) Polyolefin compositions using natural compound as antioxidant and/or heat-resistant
UY26618A1 (es) Composiciones farmacéuticas de inhibidores de la gcomposiciones farmacéuticas de inhibidores de la glucógeno-fosforilasa
AU2110199A (en) Polymer compositions providing low residue levels and methods of use thereof
TW200700521A (en) Block copolymers comprising a mixed block derived from isoprene and butadiene and compositions comprising them
IL159074A0 (en) Polymer mixture having improved rheological properties and improved shrinking behaviour
AU2003248510A1 (en) Azetidinium-functionalised polymers and compositions containing the same
AU2001272613A1 (en) Stabilising halogenated polymers with pyrroles or derivatives thereof and compositions containing them
AU2002316170A1 (en) Compositions and methods for promoting or inhibiting ndpk
AU2002344152A1 (en) Polymer compositions and uses thereof